Medscape: GLP-1s No Benefit in Stable IBD, Kiniksa Q2 (ARCALYST +55% YoY), Medicare Bridge 27 Days In

Tuesday's digest is anchored by two clinical-and-payer stories on GLP-1 receptor agonists that complicate the class's uniformly-positive narrative. First, a Medscape-published emulated randomized trial analysis using 2018-2023 US claims data found that adults with stable inflammatory bowel disease and comorbid obesity or diabetes who initiated semaglutide or tirzepatide did not have a lower risk of IBD relapse or improved safety outcomes versus non-initiators. The finding challenges the anti-inflammatory hypothesis that has been advanced in some preclinical literature and pushes back on the informal assumption that GLP-1 receptor agonists may protect against IBD flares in obese or diabetic populations. Second, the Medicare GLP-1 Bridge Program is 27 days into the July 1 launch that provides Wegovy, Zepbound KwikPen, and Foundayo at a $50 capped monthly copay for approximately 3.8 million eligible Medicare Part D beneficiaries through December 31, 2027. Actual enrollment data has not yet been released by CMS. The 26th International AIDS Conference (AIDS 2026) continues Day 2 in Rio de Janeiro with WHO's integrated primary health care workshop on sustaining HIV, TB, viral hepatitis, and STI services for key populations, plus EATG poster sessions and CHAI cost-effectiveness analyses. In the non-GLP-1 peptide industry, Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported Q2 2026 results Tuesday with ARCALYST (rilonacept, IL-1α/IL-1β trap fusion protein for recurrent pericarditis) generating $243.6 million net product revenue (+55% YoY), plus positive Phase 2 data on KPL-387. And BioPharma Dive published a post-PCAC editorial framing the July 23-24 vote as broader use of six of seven peptides despite the substantive evidence gap.